InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,463.54
(
0.08%
)
US TECH 100
18,588.00
(
0.17%
)
Dow Jones
40,539.93
(
-0.12%
)
Brent Oil
79.06
(
-0.11%
)
Bitcoin
66,842.29
(
0.03%
)
Post# of 252727
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 120153
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biocqr post# 214489

Monday, 10/23/2017 11:51:26 AM

Monday, October 23, 2017 11:51:26 AM

Post# of 252727
ENTA EDP-305 data—just to be clear:

The phase-1 portion of the trial dosed healthy volunteers; the phase-1b portion of the trial dosed patients with presumed NAFLD, based on metabolic parameters.

The above is stated in ENTA's press release, but it might not be obvious from a cursory read.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up